Management of Brain Metastases in Patients With Melanoma

摘要: Melanoma is the third most common systemic cancer that leads to brain metastases. The annual incidence of melanoma has increased over time, with metastases developing in 40% 50% patients advanced melanoma. Traditional management melanoma-related focused on symptom control as a result significant neurologic morbidity associated disease. Median overall survival for these patients, if untreated, approximately 3 months. As other metastases, multidisciplinary treatment approach includes surgery and radiation therapy typically used, historically little role systemic, cytotoxic therapy. During past decade, advancement within field genomics led identification melanoma-specific mutations, namely, v-Raf murine sarcoma viral oncogene homolog B neuroblastoma RAS homolog, well development agents target driver mutations. In addition, advent immunotherapi...